Target intelligence / Profile preview

1-acyl-sn-glycerol-3-phosphate acyltransferase 3 (AGPAT3) (AGPAT3)

Target
AGPAT3
Molecular classification
Enzyme, Acyltransferase, 1-acyl-sn-glycerol-3-phosphate acyltransferase family
01

Overview

Golgi-associated lysophospholipid acyltransferase, scientifically identified as 1-acyl-sn-glycerol-3-phosphate acyltransferase 3 (AGPAT3 or LPAAT3), is an integral membrane enzyme localized to the Golgi complex and endoplasmic reticulum [10, 14]. It plays a critical role in the Lands cycle by catalyzing the conversion of lysophospholipids, specifically lysophosphatidic acid (LPA), into phospholipids like phosphatidic acid (PA) through the addition of an acyl group [12, 15]. This enzymatic activity is essential for maintaining the specific lipid composition of organelle membranes, which in turn regulates membrane curvature and the formation of transport tubules [1, 11]. By converting cone-shaped lysophospholipids into cylindrical phospholipids, AGPAT3 acts as a negative regulator of membrane tubulation [10, 12]. Inhibition of this enzyme, notably by the compound CI-976 (PD 128042), leads to an accumulation of lysophospholipids that promote excessive Golgi tubulation and retrograde trafficking from the Golgi to the ER [5, 11]. Consequently, it is a key regulator of Golgi structure and protein trafficking, making it a subject of interest in studies of cellular organization and diseases involving secretory pathway dysfunction, such as cancer [2, 14].

Other names
Golgi-associated lysophospholipid acyltransferaseLysophosphatidic acid acyltransferase 3LPAAT3LPAAT-gamma1-AGP acyltransferase 31-acyl-sn-glycerol-3-phosphate O-acyltransferase 3
02

Mechanism of action

Lysophospholipid acyltransferase inhibition

03

Biological functions

Phospholipid biosynthesisGolgi membrane dynamicsRetrograde traffickingLands cycleMembrane tubule formation regulation
04

Disease associations

CancerMetabolic diseaseDyslipidemia
05

Safety considerations

Disruption of the secretory pathwayOff-target inhibition of ACAT (SOAT1/SOAT2)Alteration of global lipid homeostasis
06

Interacting drugs

CI-976

1 more in the full profile.

07

Biomarkers

Golgi morphology (tubulation/fragmentation)Lysophosphatidic acid (LPA) levelsPhosphatidic acid (PA) levels

Beyond the preview

Go deeper on 1-acyl-sn-glycerol-3-phosphate acyltransferase 3 (AGPAT3) (AGPAT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-acyl-sn-glycerol-3-phosphate acyltransferase 3 (AGPAT3) (AGPAT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call